Clinical Report: Efficacy and Safety of Ambroxol and Clenbuterol in Pediatrics

Overview

This meta-analysis evaluates the efficacy and safety of ambroxol hydrochloride and clenbuterol hydrochloride oral solution (AHCHOS) in pediatric patients with wheezing disorders. Results indicate significant improvements in symptom resolution and hospital stay duration without an increase in adverse events.

Background

Wheezing disorders are common in children and can lead to significant morbidity and healthcare utilization. Effective management is crucial, as these conditions often disrupt quality of life and may have long-term health implications. The exploration of adjunctive therapies like AHCHOS is essential given the variability in treatment responses and potential adverse effects associated with conventional therapies.

Data Highlights

Key Findings

• AHCHOS significantly improved overall response rates in pediatric patients with wheezing disorders.
• Combination therapy with AHCHOS reduced the duration of coughing and wheezing.
• AHCHOS led to a shorter hospital stay compared to conventional treatments.
• No increase in adverse events was observed with AHCHOS compared to standard treatment.
• The majority of studies included in the analysis were conducted in eastern China, limiting generalizability.

Clinical Implications

Clinicians may consider AHCHOS as an adjunctive therapy for pediatric patients with wheezing disorders, given its efficacy in improving symptom resolution and reducing hospital stays. However, the findings should be interpreted with caution due to the limited geographical scope of the studies.

Conclusion

AHCHOS demonstrates modest benefits in managing pediatric wheezing disorders, but further research is needed to assess its safety and efficacy in broader populations.

References

1. Frontiers | Ambroxol Hydrochloride and Clenbuterol Hydrochloride Oral Solution for Wheezing Disorders in Children in China: Evidence Mapping and Meta-Analysis
2. GINA 2025 Global Strategy for Asthma Management an
3. BMC Psychiatry (Springer) — Evaluating the Impact of Physical Activity on Anxiety and Depression in Overweight and Obese Youth: A Comprehensive Review and Meta-Analysis
4. Drugs - Real World Outcomes — Evaluating the Risk-Benefit Profile of Hydrocodone/Chlorpheniramine in Pediatric Patients for Cough Treatment
5. Drug Safety — Evaluation of the Safety Profile of On-Demand Budesonide-Formoterol in Mild Asthma: Insights from the Phase III SYGMA Trials
6. Drugs - Real World Outcomes — Incidence of Adverse Drug Reactions from Common Asthma Treatments in Hospitalized Pediatric Patients in the US, 2000–2016
7. GINA 2025 Global Strategy for Asthma Management an
8. Frontiers | Ambroxol Hydrochloride and Clenbuterol Hydrochloride Oral Solution for Wheezing Disorders in Children in China: Evidence Mapping and Meta-Analysis
9. Clenbuterol: Unapproved and unsafe | Poison Control